- Home
- INZY
INZY
Inozyme Pharma Inc.
as 05-30-2025 12:37pm EST
Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 deficiencies.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 64.9M | IPO Year: | 2020 |
| Target Price: | $15.22 | AVG Volume (30 days): | 5.3M |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.68 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.72 - $6.24 | Next Earning Date: | 05-14-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Inozyme Pharma Inc. (INZY)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Treco Douglas A | INZY | CEO & Chairman | Apr 1 '25 | Sell | $0.89 | 8,819 | $7,848.91 | 41,046 |
Latest Inozyme Pharma Inc. News
INZY Breaking Stock News: Dive into INZY Ticker-Specific Updates for Smart Investing
Zacks
8 days ago
Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More
TipRanks
10 days ago
Biotech Alert: Searches spiking for these stocks today
Zacks
11 days ago
BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz
MT Newswires
11 days ago
Piper Sandler Downgrades Inozyme Pharma to Neutral From Overweight, Lowers Price Target to $4 From $23
MT Newswires
11 days ago
TD Cowen Downgrades Inozyme Pharma to Hold From Buy, Price Target is $4
MT Newswires
11 days ago
Raymond James Downgrades Inozyme Pharma to Market Perform From Outperform
MT Newswires
11 days ago
Needham Downgrades Inozyme Pharma to Hold From Buy
Pharmaceutical Technology
11 days ago
BioMarin agrees to acquire Inozyme for $270m
Compare INZY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INZY Inozyme Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.